Iguratimod Alleviates Experimental Sjögren’s Syndrome by Inhibiting NLRP3 Inflammasome Activation
Cell Biochemistry and Biophysics · 2024-09 · 82 (3) · 2275-2283
DOI: 10.1007/s12013-024-01337-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biochemistry and Biophysics, online erschienen am 05.06.2024. Verfasst von Qi Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Shengli Oilfield Central Hospital, Dongying, Shandong, 257034, China. Hauptthemen laut MEDLINE: Sjogren's Syndrome, NLR Family, Pyrin Domain-Containing 3 Protein, Submandibular Gland, Inflammasomes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Shengli Oilfield Central Hospital, Dongying, Shandong, 257034, China.
- Department of Rheumatology and Immunology, Shengli Oilfield Central Hospital, Dongying, Shandong, 257034, China. dydengyao@126.com.
Zitieren
APA
Zhang, Q., Yang, X. R., & Deng, Y. (2024). Iguratimod Alleviates Experimental Sjögren’s Syndrome by Inhibiting NLRP3 Inflammasome Activation. Cell Biochemistry and Biophysics, 82(3), 2275-2283. https://doi.org/10.1007/s12013-024-01337-2
Vancouver
Zhang Q, Yang XR, Deng Y. Iguratimod Alleviates Experimental Sjögren’s Syndrome by Inhibiting NLRP3 Inflammasome Activation. Cell Biochemistry and Biophysics. 2024;82(3):2275-2283. doi:10.1007/s12013-024-01337-2
BibTeX
@article{Zhang2024,
author = {Zhang, Qi and Yang, Xi-Rui and Deng, Yao},
title = {Iguratimod Alleviates Experimental Sjögren’s Syndrome by Inhibiting NLRP3 Inflammasome Activation},
journal = {Cell Biochemistry and Biophysics},
year = {2024},
volume = {82},
number = {3},
pages = {2275--2283},
doi = {10.1007/s12013-024-01337-2}
}
EUVIMED